HGH Fragment 176-191 vs Retatrutide
Side-by-side comparison of key properties, dosing, and research.
Fat Loss & Metabolic
HGH Fragment 176-191GLP-1 / Weight Loss Agonists
Retatrutide- Summary
- HGH Fragment 176-191 (also known as AOD-9604) is a stabilized, modified fragment of the human growth hormone molecule corresponding to amino acids 176–191 with an addition of a tyrosine residue at the N-terminus. It retains HGH's fat-burning properties without the anabolic, diabetogenic, or IGF-1-stimulating effects.
- Retatrutide is an investigational triple receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Phase 2 trials showed an unprecedented average 24% body weight reduction at 48 weeks — exceeding any approved medication to date. It is in Phase 3 trials as of 2024.
- Half-Life
- ~30 minutes
- ~10–12 days
- Admin Route
- SubQ
- SubQ
- Research
- —
- —
- Typical Dose
- 250–500 mcg
- 0.5 mg → 1 mg → 2 mg → 4 mg → 8 mg → 12 mg
- Frequency
- 1–3 times daily
- Once weekly
- Key Benefits
- Selective fat burning without anabolic side effects
- Reduces visceral and subcutaneous fat
- No insulin resistance or blood glucose disruption
- Does not stimulate IGF-1
- May support cartilage and bone repair (at higher doses)
- No effect on growth or organ size
- ~24% body weight reduction at 48 weeks in Phase 2 (highest dose)
- Superior to both semaglutide and tirzepatide in early trial comparisons
- Triple receptor mechanism addresses multiple obesity pathways
- Significant reduction in liver fat (MASH/NAFLD indication being studied)
- Improved cardiovascular and metabolic markers
- Once-weekly dosing
- Potential for greatest weight loss of any currently investigated compound
- Side Effects
- Injection site irritation
- Temporary lethargy
- Headache (rare)
- Nausea (rare)
- Nausea and vomiting (common during titration, similar to semaglutide/tirzepatide)
- Diarrhea
- Constipation
- Heart rate increase (from glucagon receptor agonism)
- +2 more
- Stacks With
- —
- —